Rastegar D - Search Results

1

Risk factors for opioid overdose among hospitalized patients.

Vu Q, Beselman A, Monolakis J, Wang A, Rastegar D. Vu Q, et al. Among authors: rastegar d. J Clin Pharm Ther. 2018 Dec;43(6):784-789. doi: 10.1111/jcpt.12701. Epub 2018 May 23. J Clin Pharm Ther. 2018. PMID: 29797421

2

Antiretroviral medication errors among hospitalized patients with HIV infection.

Rastegar DA, Knight AM, Monolakis JS. Rastegar DA, et al. Clin Infect Dis. 2006 Oct 1;43(7):933-8. doi: 10.1086/507538. Epub 2006 Aug 22. Clin Infect Dis. 2006. PMID: 16941379

3

Preventing prescription opioid overdose deaths.

Rastegar DA, Walley AY. Rastegar DA, et al. J Gen Intern Med. 2013 Oct;28(10):1258-9. doi: 10.1007/s11606-013-2390-8. J Gen Intern Med. 2013. PMID: 23463455 Free PMC article. No abstract available.

4

The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.

Accurso AJ, Rastegar DA. Accurso AJ, et al. J Subst Abuse Treat. 2016 Feb;61:74-9. doi: 10.1016/j.jsat.2015.09.004. Epub 2015 Oct 1. J Subst Abuse Treat. 2016. PMID: 26639639

5

Treatment of opioid use disorder in primary care.

Buresh M, Stern R, Rastegar D. Buresh M, et al. Among authors: rastegar d. BMJ. 2021 May 19;373:n784. doi: 10.1136/bmj.n784. BMJ. 2021. PMID: 34011512 Review.

6

Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic.

Colburn JL, Jasinski DR, Rastegar DA. Colburn JL, et al. J Opioid Manag. 2012 May-Jun;8(3):153-60. doi: 10.5055/jom.2012.0111. J Opioid Manag. 2012. PMID: 22798175

7

Impact of a Mandated Change in Buprenorphine Formulation.

Graddy R, Rastegar DA. Graddy R, et al. J Addict Med. 2017 Nov/Dec;11(6):435-439. doi: 10.1097/ADM.0000000000000341. J Addict Med. 2017. PMID: 28742624

8

Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone.

Soeffing JM, Rastegar DA. Soeffing JM, et al. J Subst Abuse Treat. 2007 Dec;33(4):401-4. doi: 10.1016/j.jsat.2007.01.004. Epub 2007 Apr 2. J Subst Abuse Treat. 2007. PMID: 17400414

9

A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.

Fingerhood MI, King VL, Brooner RK, Rastegar DA. Fingerhood MI, et al. Subst Abus. 2014;35(2):122-6. doi: 10.1080/08897077.2013.819828. Subst Abus. 2014. PMID: 24821346

10

Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists.

Thakrar AP, Jablonski L, Ratner J, Rastegar DA. Thakrar AP, et al. Among authors: rastegar da. J Addict Med. 2022 Jan-Feb 01;16(1):122-124. doi: 10.1097/ADM.0000000000000838. J Addict Med. 2022. PMID: 33758112

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters